Aspect Partners’s Regeneron Pharmaceuticals REGN Stock Holding History

Aspect Partners’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.12K	Sell	5 -17	-77%	-$11.6K	﹤0.01%	477
2026 Q1	$17K	Hold	22	–	–	0.01%	200
2025 Q4	$17K	Hold	22	–	–	0.01%	211
2025 Q3	$12.4K	Hold	22	–	–	0.01%	269
2025 Q2	$11.6K	Sell	22 -1	-4%	-$558	0.01%	265
2025 Q1	$14.6K	Hold	23	–	–	0.01%	225
2024 Q4	$16.4K	Hold	23	–	–	0.01%	226
2024 Q3	$24.2K	Hold	23	–	–	0.01%	171
2024 Q2	$24.2K	Hold	23	–	–	0.01%	167
2024 Q1	$22.1K	Hold	23	–	–	0.02%	170
2023 Q4	$20.2K	Buy	+23	New	+$18.9K	0.01%	173

Other funds holding REGN

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return

GuoLine Advisory Singapore $1.07B AUM 26.27% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

Vest Financial Mclean, Virginia $9.52B AUM 31.6% 1-Year Est. Return

WCM

Wedge Capital Management Charlotte, North Carolina $6.06B AUM 47.24% 1-Year Est. Return

AIP

ARS Investment Partners New York $2.29B AUM 113.95% 1-Year Est. Return

Aspect Partners's REGN Position: Q2 2026 in Review

Aspect Partners reduced its Regeneron Pharmaceuticals (REGN) stake by 77% in Q2 2026, selling an estimated $11.6K and leaving 5 shares worth $3.12K. The position accounts for ﹤0.01% of the portfolio, ranked #477.

Aspect Partners first reported a position in REGN in Q4 2023 and has held it in 11 quarters since. The position peaked at $24.2K in Q3 2024. 334 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

Aspect Partners held 5 shares of Regeneron Pharmaceuticals worth $3.12K as of Q2 2026.
Aspect Partners sold 17 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $11.6K.
Regeneron Pharmaceuticals made up ﹤0.01% of Aspect Partners's portfolio in Q2 2026, its #477 holding.
Aspect Partners first reported a position in Regeneron Pharmaceuticals in Q4 2023 and has held it in 11 quarters since.
Aspect Partners's Regeneron Pharmaceuticals position peaked at $24.2K in Q3 2024.
334 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Aspect Partners's 13F filing for Q2 2026, filed 16 Jul 2026.